Atypical antipsychotic profile of NRA0045, a novel dopamine D4 receptor, 5-hydroxytryptamine2(A) (5-HT2(A)) receptor and α1 adrenoceptor antagonist

CNS Drug Reviews

Volumn 6, Issue 2, 2000, Pages 95-110

  Chaki, Shigeyuki ^a   Nakazato, Atsuro ^a   Okuyama, Shigeru ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 HT(2A) receptor; Atypical antipsychotic; D4 receptor; NRA0045; Schizophrenia

Indexed keywords

2 AMINO 4 (4 FLUOROPHENYL) 5 [1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL] 3 PYRROLIDINYL]THIAZOLE; APOMORPHINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; METHAMPHETAMINE; PHENCYCLIDINE; PRAZOSIN; RISPERIDONE; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SPIPERONE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EXTRAPYRAMIDAL SYMPTOM; HYPERACTIVITY; IC 50; NONHUMAN; PREPULSE INHIBITION; PSYCHOPHARMACOLOGY; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SWIMMING;

EID: 0033847244     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2000.tb00140.x     Document Type: Review

References (67)

1. Positive and negative symptoms in schizophrenia: A critical reappraisal
2. Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system
3. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist
4. Clozapine: A novel antipsychotic agent
5. Gating and habituation of the startle reflex in schizophrenic patients
6. 4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests
7. Central dopaminergic system: Two in vivo electrophysiological models for predicting therapeutic efficacy and neurological side effects of putative antipsychotic compounds
8. 4 receptors
9. In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats
10. Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons
11. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
12. Stimulation of immediate early gene expression by desipramine in rat brain
13. Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: The nucleus accumbens shell as a locus of antipsychotic action
14. 2 dopamine-receptor antagonists induce Fos and related proteins in rat striatal neurons
15. Treatment of schizophrenia: A clinical and preclinical evaluation of neuroleptic drugs
16. Behavioral responses to psychomotor stimulant drugs: Localization in the central nervous system
17. 35S]GTPγS binding via human D(2short) and D(2long) dopamine receptors expressed in recombinant cells
18. Pilot clinical investigation of risperidone in the treatment of psychotic patients
19. Receptor mechanisms mediating clozapine-induced c-fos expression in the forebrain
20. Muscarinic acetylcholine receptor-stimulated binding of guanosine 5'-O-(3-thiotriphosphate) to guanine-nucleotide-binding proteins in cardiac membranes
21. Catalepsy as a rodent model for detecting antipsychotic compounds with extrapyramidal side effect liability
22. Recent advances in the phencyclidlne model of schizophrenia
23. 3H]MDL 100,907: A novel selective 5-HT(2A) receptor ligand
24. Effects of NRA0045, NRA0160, and NRA0215 on regional Fos-like immunoreactivity in the rat brain
25. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT(2A) antagonist with a favorable CNS safety profile
26. 5-HT modulation of auditory and visual sensorimotor gating. I. Effects of 5-HT releasers on sound and light pre-pulse inhibition in Wistar rats
27. The effects of radio-frequency lesions of the nucleus accumbens on D-amphetamine-induced locomotor and rearing behavior in rats
28. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic patients with schizophrenia
29. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone
30. Clozapine and haloperidol produce differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Cajella
31. 4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition
32. 4 receptor selective antagonist
33. Stimulus-transcription coupling in the nervous system: Involvement of the inducible proto-oncogenes fos and jun
34. Regulation c-fos and NGF-1-A by antidepressant treatment
35. A rat model of phencyclidine psychosis
36. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced cognitive dysfunction
37. 4 and 5-hydroxytryptamine(2A) receptor antagonist, in rats
38. 4 receptor, serotonin 5-HT(2A) receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl]pyrrol idin-3-yl]thiazole (NRA0045)
39. Effect of NE-100, a novel sigma ligand, on phencyclidine-induced delayed cognitive function in rats
40. 4 receptor: Sequence, gene structure, and demonstration of expression in the cardiovascular system
41. Neuroleptic drug interactions with norepinephrine alpha-receptor binding sites in the brain
42. Thymosthenic effects of ritanserin (R55667), a centrally acting serotonin-S2 receptor blocker
43. Prepulse inhibition as a screening test for potential antipsychotics
44. Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine
45. The role of 5-HT(2A) receptors in antipsychotic activity
46. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
47. Brain dopamine receptors
48. 4
49. Antipsychotic drug doses and neuroleptic/dopamine receptors
50. Dopamine receptor pharmacology
51. Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats
52. 2 antagonist MDL 100,907 as a putative atypical antipsychotic: Behavioral, electrophysiological, and neurochemical studies
53. Effect of desipramine on dopamine receptor binding in vivo
54. 2 receptor binding study of risperidone and haloperidol
55. 2 receptor occupancy
56. 2 receptor and alpha 1-adrenoceptor antagonism
57. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients
58. Neural substrates of sensorimotor gating of the startle reflex: A review of recent findings and their implications
59. Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rats
60. The receptor occupation and plasma concentration of NKY-722, a water soluble dihydropyridine-type calcium antagonist, in spontaneously hypertensive rats
61. The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs
62. 4 receptor with high affinity for the antipsychotic clozapine
63. 4 receptor variants in the human population
64. Clozapine: A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents
65. Differential effects of classical and atypical antipsychotic compounds on A9 and A10 dopamine neurons
66. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia
67. 4 receptor